Exagen Q3 revenue beats analyst expectations

Reuters11-04

<a href="https://laohu8.com/S/XGN">Exagen</a> Q3 revenue beats analyst expectations

Overview

Exagen Q3 2025 revenue grows 38% yr/yr, beating analyst expectations
Company reports net loss for Q3 2025 despite revenue growth
Exagen expands AVISE CTD test volume and ASP in Q3 2025

Outlook

Exagen reiterates 2025 revenue guidance of $65 mln to $70 mln
Company expects positive adjusted EBITDA in Q4 2025 if revenue hits high end of range

Result Drivers

AVISE CTD TEST VOLUME - 16% growth in AVISE CTD test volume compared to Q3 2024
ASP INCREASE - Trailing twelve-month ASP for AVISE CTD increased by $37 per test over Q3 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Beat	$17.24 mln	$16.90 mln (8 Analysts)
Q3 EPS		-$0.31
Q3 Net Income		-$7.08 mln
Q3 Operating Expenses		$13.17 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Exagen Inc is $12.00, about 1.4% above its November 3 closing price of $11.83

Press Release: ID:nGNX2pS666

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580734910?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580734910","market":"us","top_or_hot":-1,"title":"Exagen Q3 revenue beats analyst expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/XGN\">Exagen</a> Q3 revenue beats analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Exagen Q3 2025 revenue grows 38% yr/yr, beating analyst expectations</p></li><li><p>Company reports net loss for Q3 2025 despite revenue growth</p></li><li><p>Exagen expands AVISE CTD test volume and ASP in Q3 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Exagen reiterates 2025 revenue guidance of $65 mln to $70 mln</p></li><li><p>Company expects positive adjusted EBITDA in Q4 2025 if revenue hits high end of range</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>AVISE CTD TEST VOLUME - 16% growth in AVISE CTD test volume compared to Q3 2024</p></li><li><p>ASP INCREASE - Trailing twelve-month ASP for AVISE CTD increased by $37 per test over Q3 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$17.24 mln</p></td><td><p>$16.90 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.31</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$7.08 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$13.17 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the healthcare facilities &amp; services peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Exagen Inc is $12.00, about 1.4% above its November 3 closing price of $11.83</p></li></ul><p>Press Release: <span>ID:nGNX2pS666</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exagen Q3 revenue beats analyst expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExagen Q3 revenue beats analyst expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/XGN\">Exagen</a> Q3 revenue beats analyst expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Exagen Q3 2025 revenue grows 38% yr/yr, beating analyst expectations</p></li><li><p>Company reports net loss for Q3 2025 despite revenue growth</p></li><li><p>Exagen expands AVISE CTD test volume and ASP in Q3 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Exagen reiterates 2025 revenue guidance of $65 mln to $70 mln</p></li><li><p>Company expects positive adjusted EBITDA in Q4 2025 if revenue hits high end of range</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>AVISE CTD TEST VOLUME - 16% growth in AVISE CTD test volume compared to Q3 2024</p></li><li><p>ASP INCREASE - Trailing twelve-month ASP for AVISE CTD increased by $37 per test over Q3 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Beat</p></td><td><p>$17.24 mln</p></td><td><p>$16.90 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.31</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$7.08 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$13.17 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the healthcare facilities &amp; services peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Exagen Inc is $12.00, about 1.4% above its November 3 closing price of $11.83</p></li></ul><p>Press Release: <span>ID:nGNX2pS666</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XGN","symbol_name":"Exagen","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG0NF:1","article_id":"2580734910","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580734910","pubTimestamp":1762261722,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exagen Q3 revenue beats analyst expectationsOverviewExagen Q3 2025 revenue grows 38% yr/yr, beating analyst expectationsCompany reports net loss for Q3 2025 despite revenue growthExagen expands AVISE ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XGN":"Exagen","BK4139":"生物科技"},"translate_title":"Exagen第三季度收入超出分析师预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XGN":0.9},"content_text":"Exagen Q3 revenue beats analyst expectationsOverviewExagen Q3 2025 revenue grows 38% yr/yr, beating analyst expectationsCompany reports net loss for Q3 2025 despite revenue growthExagen expands AVISE CTD test volume and ASP in Q3 2025OutlookExagen reiterates 2025 revenue guidance of $65 mln to $70 mlnCompany expects positive adjusted EBITDA in Q4 2025 if revenue hits high end of rangeResult DriversAVISE CTD TEST VOLUME - 16% growth in AVISE CTD test volume compared to Q3 2024ASP INCREASE - Trailing twelve-month ASP for AVISE CTD increased by $37 per test over Q3 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueBeat$17.24 mln$16.90 mln (8 Analysts)Q3 EPS-$0.31Q3 Net Income-$7.08 mlnQ3 Operating Expenses$13.17 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the healthcare facilities & services peer group is \"buy\"Wall Street's median 12-month price target for Exagen Inc is $12.00, about 1.4% above its November 3 closing price of $11.83Press Release: ID:nGNX2pS666For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580734910","isCrawlerRequest":true}